ABSTRACT

Objective: Our purpose is comparing the effectiveness of IP and IV chemotherapy in patients with epithelial ovarian cancer (EOC). This is a pilot study for improving protocol of chemotherapy for EOC.
Methods: A retrospective, single-center study included 103 patients with EOC between March 2005 and December 2022. Forty-eight patients received IV chemotherapy; 45 received IP chemotherapy. In the IP group, carboplatin (AUC5) was administered on day 1 and paclitaxel (135 mg/m2) was on day 2 through IP port, every three weeks for 6 cycles. In the IV group carboplatin and paclitaxel were administered intravenously with the same dosage and the same schedule. The primary endpoint was progression free survival.
Results: The median PFS was longer in the IP group than in the IV group (65 months vs. 59 months) with 31% lower risk of recurrence (HR=0.69, 95% CI: 0.35-1.34, P=0.27). The median PFS of stage 3 was 47 months (95% CI: 15.8-78.1) with the IP chemotherapy and 19 months (95% CI: 16.22-21.77) with IV chemotherapy (HR=0.36, 95% CI: 0.14-0.95, P=0.04). Median OS for patients of stage 3 was 110 months and 67 months in the IP group and IV group (P=0.03), respectively (HR=0.17, 95%CI: 0.03-1.08, P=0.06).
Conclusion: IP chemotherapy has a survival benefit in patients with stage 3 EOC. There were no significant differences in adverse events between two groups.

KEYWORDS

Ovary cancer, Intraperitoneal chemotherapy, Carboplatin-taxane

REFERENCES

1) Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-4.
2) McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med 1996;334:1-6.
3) Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200.
4) Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. New Engl J Med 2018;379:2495-505.
5) Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. New Eng J Med 2011;365:2484-96.
6) Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol 2023;41:2436.
7) Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New Engl J Med 2006;354:34-43.
8) Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:1331-8.
9) Lim MC, Chang SJ, Yoo HJ, et al. Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. J Clin Oncol 2017;35:s5520
10) Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22:1570-75.
11) Nagao S, Fujiwara K, Yamamoto K, et al. Intraperitoneal carboplatin for ovarian cancer—a phase 2/3 trial. NEJM Evidence 2023;2:EVIDoa2200225. doi:10.1056/EVIDoa2200225
12) Walker JL, Brady MF, Wenzel L, et al. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study, J Clin Oncol 2019;37:1380-90.
13) Fujiwara K, Armstrong D, Morgan M, Markman M. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer 2007;17:1-20.
14) DeGregorio MW, Lum BL, Holleran WM, Wilbur BJ, Sikic BI. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemoth Pharm 1986;18:235-8.
15) Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol 1992;10:1485-91.
16) Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology;2003:21:3194-200.
17) Lim MC, Chang SJ, Park B, et al. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial. JAMA Surg 2022;157:374-83.
18) Giuseppe V, Maria TG, Federica N, et al. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum- Resistant Recurrence of Ovarian Tumor: A Single-Institution Experience (ID:PARROT Trial). Ann Surg Oncol 2024;31:1207-16